-
Sector Analysis
NewAttention Deficit Hyperactivity Disorder (ADHD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Attention Deficit Hyperactivity Disorder (ADHD) market through 2032. The prevalent cases of ADHD in the 7MM will increase from 21,141,036 to 21,970,997, at an annual growth rate (AGR) of 0.4% over the forecast period. The ADHD market was valued at $11.9 billion in the 2022 baseline year. Over the 10-year forecast period, the market is projected to decline at a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tris-CAR-T in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tris-CAR-T in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tris-CAR-T in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Tris-CAR-T is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-2001 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-2001 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-2001 in Relapsed Multiple Myeloma Drug Details: ISB-2001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-2001 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-2001 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-2001 in Refractory Multiple Myeloma Drug Details: ISB-2001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-4101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DF-4101 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DF-4101 in Non-Small Cell Lung Cancer Drug Details: DF-4101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-4101 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DF-4101 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DF-4101 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-4101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DF-4101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DF-4101 in Solid Tumor Drug Details: DF-4101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-4101 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DF-4101 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DF-4101 in Renal Cell Carcinoma Drug Details: DF-4101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NM21-1480 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NM21-1480 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NM21-1480 in Non-Small Cell Lung Cancer Drug Details: NM21-1480 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Prostate Cancer Drug Details: HPN-328 is under development for the...